Riskpilot← Back to searchSign inGet full accessRarity Bioscience AB
ABActiveOrg 5593199960UppsalaResearch and experimental development on natural sciences and engineering · NACE 7210Est. 202120-49 employees
Revenue 2024
SEK 1,4M
-33% vs 2023
EBITDA margin
-1479.4%
-40% vs 2023
Equity ratio
95.3%
Financial strength
Net profit 2024
SEK -19,4M
-43% vs 2023
| Revenue | SEK 1,4M | -33% |
| EBITDA | SEK -20M | -40% |
| Net profit | SEK -19,4M | -43% |
| Total assets | SEK 70,6M | +203% |
| Equity | SEK 67,3M | +242% |
| Employees | — | — |
Legal name
Rarity Bioscience AB
Org number
5593199960
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
31 maj 2021
Share capital
SEK 73 542
Employees
20-49
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva utveckling, produktion, marknadsföring och försäljning av bioteknologiska och medicintekniska produkter och tjänster såsom exempelvis tester för att påvisa och kvantifiera specifika DNA sekvensvarianter samt därmed förenlig verksamhet.
Address
Uppsala
Email
linus.bosaeus@raritybioscience.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 28 | 115 | 2 016 | 1 352 |
| Staff expenses | — | −5 692 | −10 171 | −13 654 |
| EBITDA | −2 488 | −9 691 | −14 264 | −20 008 |
| Depreciation & amort. | −11 | −41 | −41 | −205 |
| EBIT | −2 499 | −9 733 | −14 305 | −20 214 |
| Net financials | 12 | 55 | 714 | 802 |
| Profit before tax | −2 488 | −9 677 | −13 591 | −19 412 |
| Tax | −0 | — | — | — |
| Net profit | −2 488 | −9 677 | −13 591 | −19 412 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 13 381 | 30 693 | 23 294 | 70 580 |
| Equity | 12 537 | 27 859 | 19 668 | 67 285 |
| Long-term debt | 0 | — | — | — |
| Short-term debt | 844 | 2 834 | 3 626 | 3 295 |
| Total debt | 844 | 2 834 | 3 626 | 3 295 |
EBITDA margin
-1479.4%
This company
15.8%
Market median
-9463% vs market
20212024
Equity ratio
95.3%
This company
38.2%
Market median
+149% vs market
20212024
Return on equity
-28.9%
This company
18.4%
Market median
-257% vs market
20212024
Net profit margin
-1435.3%
This company
8.1%
Market median
-17820% vs market
20212024
Asset turnover
0.02×
This company
1.12×
Market median
-98% vs market
20212024
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-06-01 – 2021-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LP Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
JE Chief Auditor | Chief Auditor | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2021 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2025 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2021 | — | — | |
LC | Board of Directors | 2022 | — | — |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2021 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Rarity Bioscience AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Linus Peter Liungman Bosaeus | Chief Executive Officer | 0 companies |
| Johan Erik Niclas Bergenmo | Chief Auditor | 0 companies |
| Hans Jarl Rutger Arnhult | Deputy Board Member | 0 companies |
| Bo Daniel Falk | Deputy Board Member | 0 companies |
| Dag Åke Ulf Landegren | Board of Directors | 0 companies |
| Alex Samar Basu | Board of Directors | 0 companies |
| Lars Anders Larsson | Board of Directors | 0 companies |
| Idar Kreutzer | Board of Directors | 0 companies |
| Nils Jorma Landegren | Deputy Board Member | 0 companies |
| Andrea Eva Ballagi Pordany | Board of Directors | 0 companies |
| Åke Mikael Smedeby | Board of Directors | 0 companies |
| Lei Chen | Board of Directors | 0 companies |
| Per Ove Öhman | Board of Directors | 0 companies |
| Jaroslav M Belotserkovsky | Board of Directors | 0 companies |
| Per Nils Jesper Matsson | Chairman | 0 companies |